Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
Ensysce Biosciences (NASDAQ:ENSC) hosted a successful symposium at the International Association for the Study of Pain (IASP) 2024 World Congress in Amsterdam. The symposium, titled 'Severe Pain: A New Chapter for Safer Analgesics', focused on innovative solutions for severe pain relief while reducing opioid abuse and overdose risks. Key discussions included:
1. Current landscape of severe pain treatment
2. new therapeutic agents in the past decade
3. Pros and cons of opioid use and genetic influences on pain
4. Ensysce's Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) technologies
5. Safety and effectiveness of PF614 and PF614-MPAR
6. Upcoming clinical studies and commercial positioning
The symposium received positive feedback on its content and Ensysce's clinical strategy.
Ensysce Biosciences (NASDAQ:ENSC) ha organizzato un simposio di successo presso il Congresso Mondiale 2024 dell'International Association for the Study of Pain (IASP) ad Amsterdam. Il simposio, intitolato 'Dolore Grave: Un Nuovo Capitolo per Analgesici Più Sicuri', si è concentrato su soluzioni innovative per il sollievo dal dolore severo, riducendo al contempo l'abuso di oppioidi e i rischi di overdose. Tra i principali argomenti trattati:
1. Scenari attuali del trattamento del dolore severo
2. Nuovi agenti terapeutici nell'ultimo decennio
3. Pro e contro dell'uso di oppioidi e influenze genetiche sul dolore
4. Tecnologie di Ensysce Trypsin Activated Abuse Protection (TAAP) e Multi-Pill Abuse Resistance (MPAR)
5. Sicurezza ed efficacia di PF614 e PF614-MPAR
6. Prossimi studi clinici e posizionamento commerciale
Il simposio ha ricevuto feedback positivi sui suoi contenuti e sulla strategia clinica di Ensysce.
Ensysce Biosciences (NASDAQ:ENSC) organizó un simposio exitoso en el Congreso Mundial 2024 de la Asociación Internacional para el Estudio del Dolor (IASP) en Ámsterdam. El simposio, titulado 'Dolor Severo: Un Nuevo Capítulo para Analgésicos Más Seguros', se centró en soluciones innovadoras para el alivio del dolor severo, mientras se reduce el abuso de opioides y los riesgos de sobredosis. Las principales discusiones incluyeron:
1. Panorama actual del tratamiento del dolor severo
2. Nuevos agentes terapéuticos en la última década
3. Pros y contras del uso de opioides e influencias genéticas en el dolor
4. Tecnologías de Ensysce Trypsin Activated Abuse Protection (TAAP) y Multi-Pill Abuse Resistance (MPAR)
5. Seguridad y eficacia de PF614 y PF614-MPAR
6. Próximos estudios clínicos y posicionamiento comercial
El simposio recibió comentarios positivos sobre su contenido y la estrategia clínica de Ensysce.
Ensysce Biosciences (NASDAQ:ENSC)는 암스테르담에서 열린 국제 통증 연구 협회 (IASP) 2024 세계 회의에서 성공적인 심포지엄을 개최했습니다. '심각한 통증: 더 안전한 진통제에 대한 새로운 장'이라는 제목의 심포지엄은 심각한 통증 완화를 위한 혁신적인 솔루션에 중점을 두었으며, 오피오이드 남용과 과다 복용 위험을 줄이는 데 중점을 두었습니다. 주요 논의 사항에는 다음이 포함되었습니다:
1. 심각한 통증 치료의 현재 상황
2. 지난 10년 동안의 새로운 치료제
3. 오피오이드 사용의 장단점 및 통증에 대한 유전적 영향
4. Ensysce의 트립신 활성화 남용 방지 (TAAP) 및 다중 알약 남용 저항 (MPAR) 기술
5. PF614 및 PF614-MPAR의 안전성 및 효과
6. 다가오는 임상 연구 및 상업적 포지셔닝
이 심포지엄은 내용과 Ensysce의 임상 전략에 대한 긍정적인 피드백을 받았습니다.
Ensysce Biosciences (NASDAQ:ENSC) a organisé un symposium réussi lors du Congrès Mondial 2024 de l'Association Internationale pour l'Étude de la Douleur (IASP) à Amsterdam. Le symposium, intitulé 'Douleur Sévère : Un Nouveau Chapitre pour des Analgésiques Plus Sûrs', s'est concentré sur des solutions innovantes pour le soulagement de la douleur sévère tout en réduisant l'abus d'opioïdes et les risques de surdosage. Les principales discussions comprenaient :
1. Paysage actuel du traitement de la douleur sévère
2. Nouveaux agents thérapeutiques au cours de la dernière décennie
3. Avantages et inconvénients de l'utilisation d'opioïdes et influences génétiques sur la douleur
4. Technologies de Ensysce Protection contre les Abus Activée par Trypsine (TAAP) et Résistance Multi-Pills aux Abus (MPAR)
5. Sécurité et efficacité de PF614 et PF614-MPAR
6. Prochains essais cliniques et positionnement commercial
Le symposium a reçu des retours positifs concernant son contenu et la stratégie clinique d'Ensysce.
Ensysce Biosciences (NASDAQ:ENSC) veranstaltete ein erfolgreiches Symposium beim Internationalen Verband zur Untersuchung von Schmerz (IASP) 2024 Weltkongress in Amsterdam. Das Symposium mit dem Titel 'Schmerzhafter Schmerz: Ein neues Kapitel für sicherere Analgetika' konzentrierte sich auf innovative Lösungen zur Linderung von starkem Schmerz und gleichzeitig zur Reduzierung des Missbrauchs von Opioiden und Überdosisrisiken. Zu den wichtigsten Diskussionspunkten gehörten:
1. Aktuelles Szenario der Behandlung von schwerem Schmerz
2. Neue therapeutische Mittel im letzten Jahrzehnt
3. Vor- und Nachteile der Verwendung von Opioiden und genetische Einflüsse auf Schmerz
4. Ensysces Trypsin Activated Abuse Protection (TAAP) und Multi-Pill Abuse Resistance (MPAR) Technologien
5. Sicherheit und Wirksamkeit von PF614 und PF614-MPAR
6. Kommende klinische Studien und kommerzielle Positionierung
Das Symposium erhielt positive Rückmeldungen zu seinen Inhalten und zur klinischen Strategie von Ensysce.
- Successful presentation of Ensysce's TAAP and MPAR technologies at a major pain management conference
- Positive feedback received on symposium content and clinical strategy
- Potential for PF614 and PF614-MPAR to address severe pain while reducing opioid abuse risks
- None.
~ PF614 and PF614-MPAR Discussed in Satellite Symposium on Severe Pain ~
SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides a summary of its successful symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium illustrated the current landscape of severe pain, including post-surgical and cancer pain treatment, and discussed potential innovative treatment options, noting the limited number of new therapeutic agents approved in the last ten years.
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences, moderated the symposium entitled: ‘Severe Pain: A New Chapter for Safer Analgesics', which featured Dr. Lars Arendt-Nielsen, Professor of Aalberg University of Medicine, Denmark, and Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences.
To begin, Dr. Arendt-Nielsen discussed the pros and cons of using opioids and the influence of genetics on pain and treatment plans. Dr. Schmidt reviewed the current options for treating pain, including use of opioid products, and the ideal profile for a new therapeutic agent. He highlighted Ensysce's Trypsin Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) agents in development and discussed the safety and effectiveness of PF614 and PF614-MPAR. Dr. Schmidt concluded with an overview of the expected clinical studies for each in the coming year and reviewed their current positioning for commercial success.
Dr. Lynn Kirkpatrick, CEO of Ensysce, commented, "The IASP World Congress on Pain is an excellent meeting where top world experts gather to discuss innovative methods to help patients suffering from pain. Our team was pleased to have the opportunity to present the clinical data on our TAAP and MPAR technology platforms which demonstrate a unique approach to protect against prescription opioid abuse and oral overdose. We received excellent feedback on both the symposium content and our clinical strategy."
The IASP has a mission to deliver pain relief throughout the world. Please find more information at the IASP website: https://www.iasp-pain.org
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View the original press release on accesswire.com
FAQ
What technologies did Ensysce Biosciences (ENSC) present at the IASP 2024 World Congress?
What was the focus of Ensysce Biosciences' (ENSC) symposium at the IASP 2024 World Congress?
What clinical developments did Ensysce Biosciences (ENSC) discuss at the IASP 2024 symposium?
How did attendees respond to Ensysce Biosciences' (ENSC) presentation at the IASP 2024 World Congress?
